Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2440 • 2019 ACR/ARP Annual Meeting
Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study
Timothy Kwok¹, Justine (Yang) Ye ², Daniel Pereira ² and Dafna Gladman ³, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Evidence thus far on the effect of psoriatic arthritis (PsA) on bone mineral density (BMD) has been inconsistent. There is also insufficient guidance surrounding…
Abstract Number: 2457 • 2019 ACR/ARP Annual Meeting
Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study
Danielle Korkus ¹, Tal Gazitt ², Arnon Dov Cohen ³, Ilan Feldhamer ⁴, Idit Lavi ², Amir Haddad ², Sari Greenberg-Dotan ⁴, Erez Batat ⁴ and Devy Zisman⁵, ¹The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel, ²Carmel Hospital, Haifa, Israel, ³Central Headquarters, Clalit Health Services,Siaal Research Center for Family Medicine and Primary Care, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel, Tel Aviv, Israel, ⁴Central Headquarters, Clalit Health Services, Tel Aviv, Israel, ⁵Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel
Background/Purpose: Patients with psoriasis and psoriatic arthritis (PsA) can develop a variety of comorbidities which may influence the therapeutic regimen and affect treatment results. Previous…
Abstract Number: 2479 • 2019 ACR/ARP Annual Meeting
Unmet Treatment Needs in Patients with Psoriatic Arthritis
Daniel Aletaha¹, Mihalina Georgallis ², Matthew Wallace ², Patrick Zueger ³ and Ruth Zeidman ², ¹Medical University of Vienna, Vienna, Austria, ²Covance Market Access & Phase IV Solutions, London, United Kingdom, ³AbbVie Inc., North Chicago
Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current…
Abstract Number: 2502 • 2019 ACR/ARP Annual Meeting
Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Jennifer Belasco¹, Sandra Garcet ¹, Mustimbo roberts ², Judilyn Fuentes-Duculan ¹, Norma Kunjravia ¹, Inna Cueto ¹, Israel Coats ¹, Xuan Li ¹, Philip Mease ³, Alice Gottlieb ⁴, Oliver FitzGerald ⁵ and James Krueger ¹, ¹The Rockefeller University, New York, NY, ²Bristol-Myers Squibb, Princeton, NJ, ³Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, New York City, NY, ⁵University College Dublin, Dublin, Ireland
Background/Purpose: Abatacept (ABA), a selective T-cell co-stimulation modulator, has been shown to improve disease activity in patients with psoriatic arthritis (PsA), but its effect on…
Abstract Number: 2855 • 2019 ACR/ARP Annual Meeting
Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program
Iain McInnes¹, Matthias Kormaksson ², Effie Pournara ³, Gregory Ligozio ², Luminita Pricop ⁴, Peter Nash ⁵, Bruce Kirkham ⁶, Kristian Reich ⁷ and Christopher Ritchlin ⁸, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Novartis Pharmaceutical Corporation, New Jersey, NJ, ³Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵University of Queensland, Brisbane, Queensland, Australia, ⁶Guy's & St Thomas' NHS Foundation Trust, London, England, United Kingdom, ⁷University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Skinflammation®, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany, Hamburg, Germany, ⁸Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY
Background/Purpose: Identifying clinically relevant patient phenotypes amidst the variability and heterogeneity of the clinical manifestations of psoriatic arthritis (PsA) is currently challenging. Using machine-learning (ML)…
Abstract Number: 823 • 2019 ACR/ARP Annual Meeting
The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Lingyi Li¹, Na Lu ¹, Eric Sayre ¹, Hui Xie ², Diane Lacaille ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…
Abstract Number: 1095 • 2019 ACR/ARP Annual Meeting
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Linh Truong¹, Nicole Ridolfi ², Eugenia Chen ² and Maida wong ³, ¹University of California, Irvine, San Diego, CA, ²University of California, Irvine, Orange, ³Tibor Rubin Veterans Affairs Medical Center, Long Beach
Background/Purpose: There is accumulating evidence demonstrating an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) among the psoriatic arthritis (PsA) population. Yet, the relationship between immunosuppressive…
Abstract Number: 1490 • 2019 ACR/ARP Annual Meeting
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Lihi Eder¹, Alexis Ogdie ² and Yujie Zhong ³, ¹Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ²Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ³School of Statistics and Management, Shanghai University of Finance and Economics, Cambridge, China (People's Republic)
Background/Purpose: The prevalence of depression is increased in patients with psoriatic arthritis (PsA). Little is known about the impact of effective control of inflammation on…
Abstract Number: 1541 • 2019 ACR/ARP Annual Meeting
Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis
Keith Betts ¹, Pankaj Patel², Jinlin Song ¹, Jing Zhao ³, Yan Wang ¹, Jenny Griffith ² and Eric Wu ⁴, ¹Analysis Group, Inc., Los Angeles, CA, ²AbbVie Inc., North Chicago, IL, ³Analysis Group, Inc., Denver, CO, ⁴Analysis Group, Inc., Boston, MA
Background/Purpose: Clinical studies have shown that a large proportion of psoriatic arthritis (PsA) patients treated with apremilast failed to achieve improved physical function or experienced…
Abstract Number: 2441 • 2019 ACR/ARP Annual Meeting
Rates of Treated Depression Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Catherine Vasilakis-Scaramozza¹, Rebecca Persson ¹, Katrina Wilcox Hagberg ¹, Steve Niemcryk ², Michael Peng ², Maria Paris ², Anders Lindholm ² and Susan Jick ³, ¹Boston Collaborative Drug Surveillance Program, Lexington, ²Celgene Corporation, Summit, ³Boston Collaborative Drug Surveillance Program and Boston University School of Public Health, Boston
Background/Purpose: Depression is common among PsA patients, but rates may differ by PsA treatment. Our study compares rates of treated depression by PsA treatment type…
Abstract Number: 2458 • 2019 ACR/ARP Annual Meeting
Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation
Carina Borst¹, Farideh Alasti ² and Daniel Aletaha ³, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Medical University of Vienna, Department of Medicine III, Division of Rheumatology, Vienna, Austria, ³Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriatic arthritis (PsA) belongs to the group of the spondylarthropathies. It is associated with psoriasis and typically seronegative for autoantibodies. PsA disease activity can…
Abstract Number: 2481 • 2019 ACR/ARP Annual Meeting
Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center
Iñigo Gonzalez-Mazon¹, Lara Sanchez-Bilbao ², Natalia Palmou-Fontana ¹, DAVID MARTINEZ-LOPEZ ³, Mónica Calderón-Goercke ⁴, DIANA PRIETO- PENA ¹, Susana Armesto-Alonso ³, Miguel A Gonzalez-Gay ² and Ricardo Blanco ², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Hospital Marqués de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Uveitis is an extra articular manifestation of psoriatic arthritis (PsA). Uveitis may be more chronic Biological therapy, especially monoclonal TNF inhibitors, are useful to…
Abstract Number: 2503 • 2019 ACR/ARP Annual Meeting
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Frank Behrens¹, Philipp Sewerin ², Eugenio de Miguel ³, Yusuf Patel ⁴, Anastas Batalov ⁵, Eva Dokoupilova ⁶, Christine Kleinmond ⁷, Effie Pournara ⁸, Ankita Shekhawat ⁹, Claudia Jentzsch ¹⁰, Annette Wiedon ¹⁰ and Xenofon Baraliakos ¹¹, ¹CIRI/Rheumatology and Fraunhofer TMP, Goethe-University, Frankfurt, Germany, ²Department of Rheumatology & Hiller Research Unit, University Hospital Düsseldorf,, Duesseldorf, Germany, ³Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, ⁴Hull University Teaching Hospitals, Hull, United Kingdom, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶MEDICAL PLUS s.r.o., Uherske Hradiste, University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Uherské Hradiště, Czech Republic, ⁷ClinProject GmbH, Eurasburg, Germany, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland, ⁹Novartis Healthcare Pvt. Ltd., Hyderabad, India, ¹⁰Novartis Pharma GmbH, Nürnberg, Germany, ¹¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany
Background/Purpose: Enthesitis is a common feature of Spondyloarthritis (SpA)1. Enthesitis at the Achilles tendon is an important manifestation with impact on function which is often…
Abstract Number: 2856 • 2019 ACR/ARP Annual Meeting
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Burkhard Moeller¹, Eleftherios Papagiannoulis ², Lisa Christ ³, Adrian Ciurea ⁴, Thomas Hugle ⁵, Ruediger B. Mueller ⁶, Michael J. Nissen ⁷, Almut Scherer ⁸, Godehard Scholz ³, Peter M. Villiger ¹ and Nikhil Yawalkar ³, ¹University Hospital Bern, Bern, Switzerland, ²SCQM Zurich, Zurich, Switzerland, ³Inselspital-University Hospital Bern, Bern, Switzerland, ⁴University Hospital Zürich, Zürich, Switzerland, ⁵University Hospital Lausanne, Lausanne, Switzerland, ⁶Clinic of Rheumatology, Medical University Hospital Aarau, Aarau, Aargau, Switzerland, ⁷University Hospital Geneva, Geneva, Switzerland, ⁸SCQM Foundation, Zürich, Switzerland
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) were the first approved biological disease modifying antirheumatic drugs (bDMARDs) for psoriatic arthritis (PsA). IL-12/23 and IL-17-specific antibodies provide…
Abstract Number: 835 • 2019 ACR/ARP Annual Meeting
High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Herman Mann ³, Tore Kvien ⁴, Michael J. Nissen ⁵, Maria José Santos ⁶, Dan Nordström ⁷, Lennart Jacobsson ⁸, Ziga Rotar ⁹, Bjorn Gudbjornsson ¹⁰, Süleyman Serdar Koca ¹¹, Catalin Codreanu ¹², Manuel Pombo-Suarez ¹³, Irene van der Horst-Bruinsma ¹⁴, Anne Gitte Loft ¹⁵, Karel Pavelka ³, Eirik Kristianslund ¹⁶, Burkhard Moeller ¹⁷, Elsa Vieira-Sousa ¹⁸, Anna Mari Hokkanen ¹⁹, Ulf Lindström ²⁰, Matija Tomsic ²¹, Thorvardur J Love ²², Abdurrahman Tufan ²³, Ruxandra IONESCU ²⁴, Carlos Sánchez-Piedra ²⁵, Marleen van de Sande ²⁶, Gary Macfarlane ²⁷, Florenzo Iannone ²⁸, Lise Hyldstrup ², Mikkel Østergaard ²⁹ and Merete Lund Hetland ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Geneva, Geneva, Switzerland, ⁶Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ⁷Department of Medicine, ROB-FIN, Helsinki University Hospital and Helsinki University, Helsinki, Finland., Helsinki, Finland, ⁸Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden, ⁹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹⁰Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹¹Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ¹²Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Bern, Bern, Switzerland, ¹⁸Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ¹⁹Helsinki University Hospital, Helsinki, Finland, ²⁰University of Gothenburg, Gothenburg, Sweden, ²¹Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ²³Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁶Amsterdam UMC, Amsterdam, Netherlands, ²⁷University of Aberdeen, Aberdeen, United Kingdom, ²⁸Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁹Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³⁰DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common1 and may reduce the likelihood of remission following tumor necrosis factor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].